Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.36 |
| ▸ | CTSL | P07711 | 3/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5900915 | 0.81 | MEN1 (0.44) | KMT2ACTSKCTSSITGB3ITGA2B | |
| SCHEMBL8604933 | 0.80 | GRIN2B (0.30) | — | |
| SCHEMBL6777217 | 0.77 | KMT2A (0.36) | KMT2ACTSKCTSSITGB3ITGA2B | |
| SCHEMBL7378319 | 0.76 | DPP4 (0.36) | — | |
| Hydrochloric Acid SCHEMBL6338693 | 0.75 | DPP4 (0.35) | — | |
| SCHEMBL5901089 | 0.75 | EPHX1 (0.33) | — | |
| SCHEMBL9704275 | 0.74 | CTSL (0.49) | KMT2AITGB3ITGA2BCTSL | |
| SCHEMBL9703231 | 0.74 | CTSL (0.49) | KMT2AITGB3ITGA2BCTSL | |
| SCHEMBL5900918 | 0.74 | MEN1 (0.45) | KMT2ACTSKCTSSITGB3ITGA2B | |
| SCHEMBL7442132 | 0.73 | HTR2C (0.33) | CTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774110-B2 | ANTITHROMBOTIC ACTIVITY AND HIGH ORAL BIOAVAILABILITY; E.G. N-AMINOSULFONYL-D-DIPHENYLALANYL-L-PROLYL-((4-AMIDINOPHENYL)METHYL)AMIDE | LG LIFE SCIENCES LTD. (KR) | 2004-08-10 | — | — | US | disclosed |
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | LG LIFE SCIENCES LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | F2, SERPINC1, TFPI | KMT2A 4314/4885CTSK 556/4885CTSS 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.